top of page

NCI-2023-03139

A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors


This study is investigating the use of a new medicine called IDE161 in participants with advanced solid tumors. The main purpose of the study is to evaluate the safety and efficacy of IDE161 in this patient population. The researchers aim to assess how well IDE161 works in shrinking tumors and whether it has manageable side effects.


For more information about the trial, click the link below:

Clinical Trial Site: Columbia


To see all available clinical trials click here.



Recent Posts

See All

NCI-2023-00614

A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of...

NCI-2021-00222

NRG-BR007: A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone...

NCT01042379

I-SPY TRIAL: Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2. This research...

Comments

bottom of page